NutriBand Inc. 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31 , 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 000-55654 NUTRIBAND INC. (Exact name of registrant as specified in its charter) Nevada 81-1118176 (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) 121 South Orange Ave. , Suite 1500 , Orlando , FL 32801 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (407) 377-6695 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock NTRB The Nasdaq Stock Market LLC Warrants NTRBW The Nasdaq Stock Market LLC Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ☐ Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections. Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $ 44,975,804 as of July 31, 2024. As of May 13, 2025, the registrant had 11,154,171 shares of common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE None . PART IV Item 15. Exhibits, Financial Statement Schedules. (1) Financial Statements (2) Exhibits Exhibit Number Description 1.1 [Reserved] 3.1A Articles of Incorporation. (1) 3.1B Amendment to Articles of Incorporation, filed May 12, 2016. (1) 3.1 Certificate of Amendment filed January 21, 2020. (Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020). 3.1C Certificate of Change, filed with the Nevada Secretary of State on August 4, 2022. (13) 3.2 By-laws (1) 3.2B Amended and Restated By-Laws adopted January 21, 2022. (12) 4.3 Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC and Platinum Point Capital LLC (6) 4.4 Form of convertible 6% promissory note issued pursuant to Exhibit 4.3 (6) 4.10 Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC (6) 4.14† 2021 Employee Stock Option Plan. (11) 4.15† Form of Stock Option Grant Notice. (11) 4.16 Form of Common Stock Purchase Warrant issued in the Company’s initial public offering in 2021 (9) 4.17 Form of Warrant issued to the Representative. (14) 4.18† 2024 Amended and Restated Stock Option Plan, adopted March 20, 2024. (15) 4.19 Form of Common Stock Purchase Warrant issued in 2024 Equity Financing (18) 5.1 [Reserved] 10.1 Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and/or his nominee (1) 10.4 Acquisition agreement dated April 5, 2018 between the Company and 4P Therapeutics LLC. (3) 10.5† Form of agreement with independent directors. (4) 10.6 Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea (Best Choice), Inc. (4) 10.15† Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company. (5) 10.16† Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company. (5) 10.17† Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company. (5) 10.18† Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company. (5) 10.19 Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC. (7) 10.20 Security Agreement, between the Company and Pocono Coated Products, LLC. (7) 10.21 Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC. (7) 10.22 License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd. (8) 10.23 Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd. (8) 10.24 Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd. (8) 10.25 Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC (8a) 10.26 Services Agreement dated October 4, 2021, between Active Intelligence, LLC and Diomics Corporation. (10) 10.27† Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan. (12) 10.28† Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik. (12) 10.29† Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman. (12) 10.30 Creditline Promissory Note, dated July 13, 2023. (16) 10.31 Conversion Agreement, dated December 19, 2023. (17) 10.32 Form of Subscription Agreement for April 19, 2024 Equity Financing (19) 10.33 Form of Note Conversion Agreement dated May 13, 2024 20 10.35 Commercial Development and Clinical Supply Agreement (“Agreement”), made on January 4, 2023, between Kindeva Drug Delivery, L.P. and 4P Therapeutics, LLC. 10.36 Amendment No. 1, dated as of February 4, 2025, to the Commercial Development and Clinical Supply Agreement, by and between Kindeva Drug Delivery L.P. and 4P Therapeutics, LLC 31.1* Certification of Principal Executive Officer pursuant to Rule 13A-14(A)/15D-14(A) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Principal Financial Officer pursuant to Rule 13A-14(A)/15D-14(A) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1* Certification of Principal Executive and Financial Officers Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002). 32.2* Certification of Principal F inancial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002). 101.INS* Inline XBRL Instance Document. 101.SCH* Inline XBRL Taxonomy Extension Schema Document. 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 1 * Filed herewith. † Executive compensation plan or arrangement. (1) Filed as exhibit to the Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference. (2) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on January 27, 2020 and incorporated herein by reference. (3) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference. (4) Filed as an exhibit to the Company’s annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference. (5) Filed as an exhibit to the Company’s Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference. (6) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on November 4, 2019, and incorporated herein by reference. (7) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 4, 2020, and incorporated herein by reference. (8) Filed as exhibits to the Company’s report on Form 8-K, which was filed with the Commission on March 11, 2021, and incorporated herein by reference. (8a) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 1, 2021, and incorporated herein by reference. (9) Filed as Exhibit 4.12 to Amendment 2 to the Company’s Registration Statement on Form S-1, which was filed with the Commission on October 1, 2021. (10) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on October 12, 2021, and incorporated herein by reference. (11) Filed as an exhibit to the Company’s Registration Statement on Form S-8, which was filed with the Commission on November 5, 2021, and incorporated herein by reference. (12) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Commission on January 27, 2022, and incorporated herein by reference. 2 (13) Filed as Exhibit 3.1C to the Company’s Current Report on Form 8-K, which was filed with the Commission on August 10, 2022, and incorporated herein by reference. (14) Filed as an exhibit to the Company’s Registration Statement on Form S-1, which was filed with the Commission on June 26, 2023, and incorporated herein by reference (15) Filed as Exhibit 4.16 to the Company’s Amendment No. to its Current Report on Form 8-K, which was filed with the Commission on March 28, 2024 and incorporated herein by reference. (16) Filed as Exhibit 10.30 to the Company’s Current Report on Form 8-K, which was filed with the Commission on July 14, 2023. (17) Filed as Exhibit No. 10.31 to the Company’s Current Report on Form 8-K, which was filed with the Commission on December 29, 2023. (18) Filed as Exhibit No. 4.19 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024. (19) Filed as Exhibit No. 10.32 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024. (20) Filed as Exhibit No. 10.33 to the Company’s Current Report on Form 8-K, which was filed with the Commission on May 21, 2024. (b) Financial Statement Schedules All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto. ITEM 16. FORM 10-K SUMMARY Not applicable. 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: May 13, 2025 NUTRIBAND INC. By: /s/ Gareth Sheridan Gareth Sheridan Chief Executive Officer By: /s/ Gerald Goodman Gerald Goodman Chief Financial Officer (Principal Financial and Accounting Officer) Signature Title Date /s/ Gareth Sheridan Chief Executive Officer and Director May 13, 2025 Gareth Sheridan /s/ Serguei Melnik Director May 13, 2025 Serguei Melnik Director Sergei Glinka /s/ Radu Bujoreanu Director May 13, 2025 Radu Bujoreanu /s/ Mark Hamilton Director May 13, 2025 Mark Hamilton /s/ Stefani Mancas Director May 13, 2025 Stefani Mancas /s/ Irina Gram Director May 13, 2025 Irina Gram 4